Pillar5 Pharma Inc. – FDA 483, Jun 5, 2026

Pillar5 Pharma Inc. in Arnprior, a drug manufacturer, received a Form 483 citing significant deficiencies in its aseptic processing and quality control systems. The inspection revealed recurring microbiological contamination in sterile drug product manufacturing, inadequate investigations into sterility failures and environmental monitoring excursions, and incomplete batch production records. These issues indicate a high risk to product quality and patient safety, with affected batches already distributed to the U.S. market.